Mode
Text Size
Log in / Sign up
N/A Completed N=4,167

Study of FORTEO Use in Subjects in the Community Setting

Source: ClinicalTrials.gov NCT01078805 ↗
Enrolled (actual)
4,167
Serious AEs
10.6%
Results posted
Jun 2012
Primary outcomePrimary: Percentage of Participants With Non-Vertebral Fragility Fractures — 1.42; 0.91; 0.70; 0.81 Percentage of participants — p=0.0177

Summary

The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Non-Vertebral Fragility Fractures
1.42; 0.91; 0.70; 0.81 0.0177 sig
SECONDARY
Percentage of Participants With Clinical Vertebral Fractures
0.67; 0.40; 0.35; 0.35 0.0689
SECONDARY
Percentage Change From Baseline in Back Pain Score by Visual Analog Scale (VAS) at 24 Month Endpoint
-36.2 <0.001 sig
SECONDARY
Percentage Change From Baseline in Pain Score by Visual Analog Scale (VAS) at 24 Month Endpoint
-24.9 <0.001 sig
SECONDARY
Treatment Adherence
72.5; 272.5; 450.7; 743.7 —
SECONDARY
Percentage Change From Baseline in Bone Mineral Density (BMD) at Month 24 Endpoint
2.569; 0.626; 1.532; 6.419; 3.766; 2.604 —
SECONDARY
Percentage Change From Baseline in Bone Mineral Content (BMC) at Month 24 Endpoint
4.187; 7.243; 5.716; 20.774; 8.303; 4.968 —
SECONDARY
Percentage Change From Baseline in Bone Area at Month 24 Endpoint
2.231; 4.680; 1.828; 3.907; 2.648; 3.395 —
SECONDARY
Physician Criteria for Initiating FORTEO Therapy
— —

Eligibility Criteria

Inclusion Criteria

  • Men and women who are judged by the study physician to be suitable for FORTEO therapy. The FORTEO product labeling specifies those individuals diagnosed with osteoporosis who are considered to be at high risk for fracture

Exclusion Criteria

  • Subjects who have an increased baseline risk for osteosarcoma. These include Paget's disease of bone, pediatric populations and young adult patients with open epiphyses, prior external beam or implant radiation therapy involving the skeleton
  • Subjects who have administered FORTEO or PTH therapy for more than two weeks directly before study entry
  • Subjects who have completed a course of FORTEO or PTH therapy of at least 18 months duration before study entry
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01078805). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search